|Bid||15.66 x 800|
|Ask||17.40 x 800|
|Day's Range||15.18 - 16.38|
|52 Week Range||14.26 - 20.00|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||25.50|
Atreca has a highly differentiated approach to antibody drug discovery that moves completely away from the biologically or genetically derived hypotheses that are traditionally used to inform target selection, Willey said in a Monday initiation note.
Atreca, Inc. (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, today announced the appointment of Lisa L. Decker, Ph.D., as Chief Business Officer and Courtney J. Phillips as General Counsel. As Chief Business Officer, Dr. Decker will lead Atreca’s corporate development function, including its strategic partnering initiatives and alliance management.
Atreca, Inc. (NASDAQ: BCEL ) shares opened for trade Thursday morning at $19.90. The IPO of 7.35 million shares was priced at $17. Atreca is a biopharma company that uses its platform to discover and develop ...
REDWOOD CITY, Calif., June 19, 2019 -- Atreca, Inc. (Nasdaq: BCEL), a biopharmaceutical company utilizing its differentiated platform to discover and develop novel.
Cancer biotechs are the hottest among drug development companies, given the lucrative market opportunity before them. One such company is testing the IPO waters this week. The IPO Terms Redwood, California-based ...
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . The IPO dates below are expected but not confirmed. Stoke Therapeutics, Inc. (STOK) will issue 6.7 million shares between ...